Accuryn Medical has developed the Accuryn Monitoring System, a next-generation smart device that transforms traditional Foley catheters into advanced monitoring tools. This system is designed to enhance the early detection and management of acute kidney injury (AKI) by providing real-time data on urine output and intra-abdominal pressure (IAP). By combining these metrics, the Accuryn Monitoring System can predict AKI up to 33.6 hours earlier than standard care, allowing for timely interventions that can significantly improve patient outcomes. The technology aims to address the challenges associated with inaccurate urine output measurements, particularly in catheterized patients, and highlights the critical link between kidney health and intra-abdominal conditions.

In addition to its monitoring capabilities, Accuryn Medical emphasizes the importance of predictive health in clinical practice. The system automates clinical data capture and visualizes trends, enabling healthcare providers to act sooner and spend more time with patients. This proactive approach is particularly vital given the high mortality rate associated with AKI, which affects hundreds of thousands of patients annually in the U.S. By facilitating earlier recognition of AKI risk, the Accuryn Monitoring System supports healthcare professionals in implementing timely interventions, ultimately aiming to protect kidney function and improve overall patient care.

United States

Accuryn Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence.

Currently, Accuryn Medical is developing a predictive health platform to help medical teams better predict adverse outcomes in critical care settings. The Accuryn® Monitoring System is not cleared for prediction of disease states or clinical conditions.

Accuryn Medical

Company Details